A phase 1 trial of RTX-240, an allogeneic engineered red blood cell with cell -surface expression of 4-1 BBL and trans-presented IL-15, in patients with advanced solid tumors

Category Primary study
JournalCancer Research
Year 2021
This article has no abstract
Epistemonikos ID: a4307481e422f6b57551252338c72cfbe5a2fb19
First added on: Feb 13, 2025